Fig. 6

Biological implications of circLIFR in bladder cancer. a, b Response of T24-CDDP expressing vector or circLIFR xenografts to treatment with PBS or CDDP. The tumors on the 28th day of the treatments were shown (a); Graph showing the weight of tumors at the end of the treatment (b). Data were mean ± SD. ns, not significant, **P < 0.01, ***P < 0.001 (Student’s t-test). c Overall survival of T24-CDDP expressing vector or circLIFR xenografted mice treated with PBS or CDDP. P-value was calculated using a log-rank test. ns, not significant, **P < 0.01, ***P < 0.001. d, e The ultrasound images of orthotopic xenograft bladder tumor model established by T24-CDDP expressing vector or circLIFR, along with PBS or CDDP treatment. The low echo area with irregular surface between two lines represented the tumor and the echo free area inside the red line was the urine in urinary bladder. White line, the wall of urinary bladder; Red line, the convex surface of tumor toward the bladder lumen. Data were mean ± SD. ns, not significant, **P < 0.01, ***P < 0.001 (Student’s t-test). f, g Efficacy of CDDP therapy against the circLIFR^low/MSH2^low (patient #135 and patient #150) and circLIFR^high/MSH2^high (patient #348 and patient #615) PDX xenografts. Data were mean ± SD. ns, not significant, ****P < 0.0001 (Student’s t-test). h, i) Immunohistochemical images of MSH2, pATM, and p73 and TUNEL staining on circLIFR^low/MSH2^low (patient #135 and patient #150) and circLIFR^high/MSH2^high (patient #348 and patient #615) PDX xenografts. Scale bar: 50 μm